Breaking Finance News

A report released today by H.C. Wainwright about Dicerna Pharmaceuticals (NDAQ:DRNA) raises the target price to $5.00

Dicerna Pharmaceuticals (NDAQ:DRNA) had its stock price target increased to $5.00 by H.C. Wainwright in a report issued 5/24/2017. The increased target suggests a potential upside of 0.51% from the company's last stock close price.

On 5/23/2017, H.C. Wainwright released a statement for Dicerna Pharmaceuticals (NDAQ:DRNA) increased the target price from $0.00 to $5.00. At the time, this indicated a possible upside of 0.53%.

Boasting a price of $3.31, Dicerna Pharmaceuticals (NDAQ:DRNA) traded -1.52% lower on the day. With the last close up 6.92% from the two hundred day moving average, compared to the S&P 500 which has increased 0.01% over the same time. DRNA has recorded a 50-day moving average of $3.20 and a 200-day moving average of $3.02. 38,276 shares of DRNA traded hands, down from an average trading volume of 167,895

Recent Performance Chart

Dicerna Pharmaceuticals (NDAQ:DRNA)

Dicerna Pharmaceuticals has a 52 week low of $2.42 and a one year high of $6.10 Dicerna Pharmaceuticals’s market capitalization is currently $0.

In addition to H.C. Wainwright reporting its target price, a total of 4 firms have issued a report on the stock. The consensus target price is $14.50 with 3 firms rating the stock a strong buy, 1 broker rating the stock a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and lastly zero brokerages rating the company a sell.

General Company Details For Dicerna Pharmaceuticals (NDAQ:DRNA)

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.